The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm ...

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...